Red Cross announces blood supply crisis
A shortage of blood supply is reported, affecting availability of blood products and transfusions.
Source →The trace
How it reaches your house.
Starting from Blood products, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Whole Blood (Volunteer Donation) →Shortage riskWhole blood donations are a critical, high-strength input to blood products, so a donation shortfall directly constrains product availability.
98% confidenceHuman Source Plasma (Paid Donation) →Shortage riskBlood products are almost entirely dependent on human source plasma (dependency strength 0.99), so a plasma donation crisis should directly reduce availability.
96% confidenceBlood products →Shortage riskHospitals
Hospital transfusion supply is directly tightened because the Red Cross is rationing blood deliveries to hospitals.
“Red Cross is now limiting distributions of type O blood to hospitals.”
96% confidenceCited →Whole Blood (Volunteer Donation) →Shortage riskAmerican Red Cross Blood Services
The Red Cross itself reported a national blood supply crisis driven by a four-year low in donations and limiting O blood distributions, which directly supports a supply shortage at this blood service.
96% confidenceBlood products →DelaysPatients
Patients face delayed access to transfusions because some are already being forced to wait for needed blood.
“Patients may already be feeling the consequences of the blood crisis, with some forced to wait for the blood they desperately need.”
94% confidenceCited →American Red Cross Blood Services →Shortage riskWhole Blood (Volunteer Donation)
Red Cross says blood donations fell to a four-year summer low and it has less than a one-day supply of type O blood, so its core input—whole-blood donations—is scarce; the dependency is material because the Red Cross accounts for a large share of U.S. blood supply.
93% confidenceBlood products →Shortage riskWhole Blood (Volunteer Donation)
The reported blood-donation collapse directly constrains volunteer whole-blood supply, which is a critical input to blood products.
90% confidenceBlood products →Shortage riskHuman Source Plasma (Paid Donation)
The blood crisis is driven by a sharp donation shortfall, and blood products critically depend on donor plasma, so this input becomes scarce.
88% confidenceHuman Source Plasma (Paid Donation) →Shortage riskCSL Behring sources about 33% of this input, with low substitutability and an 18-month replacement lead time, so a plasma shortage is likely to constrain supply.
87% confidenceHuman Source Plasma (Paid Donation) →Shortage riskGrifolsGRFS.MC
Grifols sources about 25% of this input and faces low substitutability with an 18-month replacement lead time, making it vulnerable to a plasma shortage.
84% confidenceWhole Blood (Volunteer Donation) →Shortage riskVitalant (formerly Blood Systems / United Blood Services)
As a major blood collector dependent on volunteer donations, a broad donor shortfall would tighten Vitalant's available supply.
83% confidenceWhole Blood (Volunteer Donation) →Shortage riskThe crisis is explicitly national, so the U.S. blood supply as a country-level node is directly affected by the donation shortfall.
82% confidenceHuman Source Plasma (Paid Donation) →Shortage riskTakeda Plasma-Derived Therapies4502.T
Takeda's plasma-derived therapies business sources roughly 20% of this input, so reduced paid-donation plasma should tighten supply for its products.
82% confidenceHuman Source Plasma (Paid Donation) →Shortage riskOctapharma sources about 12% of this input with low substitutability and long replacement lead time, so it should face a smaller but still real supply squeeze.
79% confidenceWhole Blood (Volunteer Donation) →Shortage riskNew York Blood Center Enterprises (NYBC)
NYBC's blood collection operations depend on volunteer donations, so reduced donations should flow through as a supply shortage there as well.
79% confidenceHop 2
Octapharma AG →Shortage riskHuman Source Plasma (Paid Donation)
Octapharma depends on paid human plasma for a meaningful share of supply, and the low substitutability plus 18-month replacement lead time make a blood-donation crisis likely to make this input scarcer.
86% confidenceTakeda Plasma-Derived Therapies →Shortage riskHuman Source Plasma (Paid Donation)
A blood supply crisis reduces available donated blood products and plasma, directly constraining Takeda's human source plasma input; the supplied edge implies this is a meaningful but not sole dependency (20% share).
71% confidenceUnited States →Delays
Where it lands
What you buy, and what you own.
Goods you buy
Blood products
In the MyPRIA app, this is checked against your own holdings.